文献速递认知障碍与痴呆

知情者报告的记忆减退与阿尔茨海默病临床连续谱中认知和脑退化的关联

Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
PubMed 文献 · Neurology · 2023-04-21

本研究基于IMAP+主要队列和ADNI复制队列,评估知情者报告的主观记忆减退与淀粉样蛋白沉积、认知和神经退化的关联。结果显示,在轻度认知障碍患者中,知情者报告与更高的淀粉样蛋白PET摄取强烈相关,并在ADNI中复制且扩展至神经退化。纵向分析表明,基线知情者报告可预测轻度认知障碍和主观认知下降患者的认知下降及淀粉样蛋白PET增加。

要点

  • 在轻度认知障碍患者中,知情者报告与更高的淀粉样蛋白PET摄取强烈相关(IMAP+ β=0.48,p=0.003)。
  • 在主观认知下降和轻度认知障碍患者中,知情者报告与更低的认知表现相关。
  • 纵向分析显示,基线知情者报告预测轻度认知障碍和主观认知下降患者的全局认知下降。

核心结论

  • 知情者报告在轻度认知障碍患者中尤其相关,与更高的淀粉样蛋白PET摄取强烈相关,提示由阿尔茨海默病导致的损害。

研究设计与样本

  • 研究纳入IMAP+主要队列110名参与者(32名认知未受损对照、25名主观认知下降、35名轻度认知障碍、18名阿尔茨海默型痴呆)和ADNI复制队列731名参与者(157名对照、84名主观认知下降、369名轻度认知障碍、121名阿尔茨海默型痴呆),均接受多模态神经影像和神经心理评估。
  • IMAP+参与者随访数据长达36个月用于纵向分析,知情者报告分别用认知困难量表和日常认知量表测量。
  • 采用一般线性模型评估横断面关联,线性混合效应模型评估纵向关联。

主要发现

  • 在IMAP+中,知情者报告越高与轻度认知障碍患者更高的淀粉样蛋白PET摄取强烈相关(β=0.48,p=0.003),并与主观认知下降患者更低的全局认知(β=-0.41,p=0.04)和轻度认知障碍患者更低的记忆表现(β=-0.37,p=0.03)相关。
  • 在ADNI中,轻度认知障碍患者的发现被复制:知情者报告与淀粉样蛋白PET(β=0.25,p<0.001)和记忆(β=-0.22,p<0.001)相关,并扩展至阿尔茨海默病特征区域的神经退化(β=-0.2,p<0.001)。
  • IMAP+纵向分析显示,知情者报告与轻度认知障碍患者(估计值-0.74,SE 0.26,p=0.005)和主观认知下降患者(估计值-0.36,SE 0.26,p=0.02)的全局认知下降随时间相关,较高的基线知情者报告还预测淀粉样蛋白PET随时间增加(估计值0.008,SE 0.003,p=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Studies are sparse regarding the association between the informant-reported subjective memory decline (informant report) and Alzheimer disease (AD) biomarkers. This study thus aimed at determining the clinical relevance of the informant report throughout the AD clinical continuum, by assessing its specific relationships with amyloid deposition, cognition, and neurodegeneration. METHODS: Participants from the Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce (IMAP+) primary cohort and the Alzheimer Disease Neuroimaging Initiative (ADNI) replication cohort were included; all underwent multimodal neuroimaging and neuropsychological assessments. Follow-up data of IMAP+ participants over up to 36 months were also used for longitudinal analyses. The informant report was measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI). General linear models were used to assess the cross-sectional associations between the informant report and amyloid-PET, cognitive performances, and neurodegeneration (atrophy and hypometabolism) in Alzheimer signature areas; while longitudinal links were assessed in IMAP+ with linear mixed-effects models. RESULTS: A total of 110 IMAP+ participants were included, including 32 cognitively unimpaired older individuals (controls, age: 70.91 ± 6.57 years, female: 50%), 25 patients with subjective cognitive decline (SCD, 65.88 ± 6.64, 40%), 35 with mild cognitive impairment (MCI, 72.49 ± 7.5, 34%), and 18 with Alzheimer-type dementia (AD dementia, 68.17 ± 8.59, 28%). Seven hundred thirty-one ADNI participants were included, including 157 controls (74.21 ± 5.95, 55%), 84 with SCD (72.00 ± 5.41, 63%), 369 with MCI (71.84 ± 7.4, 44%), and 121 with AD dementia (74.29 ± 7.75, 40%). In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48, p = 0.003), and to lower cognitive performance in patients with SCD (global cognition, β = -0.41, p = 0.04) and MCI (memory, β = -0.37, p = 0.03). Findings in patients with MCI were replicated in the ADNI (amyloid-PET, β = 0.25, p < 0.001; memory, β = -0.22, p < 0.001) and extended to neurodegeneration in AD signature areas (β = -0.2, p < 0.001). Longitudinal analyses in IMAP+ showed links with global cognitive decline over time in patients with MCI (estimate -0.74, SE 0.26, p = 0.005) and SCD (estimate -0.36, SE 0.26, p = 0.02) where a higher baseline informant report also predicted an increased amyloid-PET over time (estimate 0.008, SE 0.003, p = 0.02). DISCUSSION: Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT01638949.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kuhn E, Perrotin A, La Joie R, et al. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum. Neurology. 2023. PMID: 37085328. doi:10.1212/WNL.0000000000207338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。